Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Medtech Tags
  5. Medtech

Medtech

Thumbnail
June 20, 2022

Up-and-down test sales and a bigger Medtronic: medtech in 2028

Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.

Thumbnail
June 16, 2022

Testing times for Roche despite new Covid assay

Article image
Vantage logo
June 15, 2022

To back, or back away from, digital health?

Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.

Article image
Vantage logo
June 15, 2022

Boston makes a Korea change

Article image
Vantage logo
June 14, 2022

A new multiple sclerosis device steps forward

Article image
Vantage logo
June 01, 2022

Sernova gets under the skin

The company believes its new combination technology can make insulin injections a thing of the past.

Article image
Vantage logo
May 26, 2022

Medtronic downsizes, but not sizeably

Article image
Vantage logo
May 25, 2022

A new kind of liquid biopsy

Article image
Vantage logo
May 23, 2022

Diagnostics beat implants in the race to market

Roche had the most innovative approvals over the last five years – but took second place in terms of speed.

Article image
Vantage logo
May 20, 2022

Pfizer and its Sidekick snare a new approval

Article image
Vantage logo
May 17, 2022

Vertex’s halt does not deter Sernova and Evotec

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.